In addition, Swanson and Volkow showed that even at clinical doses, MPH administered intravenously, not orally, would produce reinforcing effects like euphoria while binding more than 60% DA transporters [84], suggesting that both doses and rapid escalation in serum are crucial for MPH induced addiction and psychiatric side effects. The gene discussed is SLC6A3; the disease is Euphoria.